Immatics N.V. (IMTX)
Immatics develops PRAME-targeted cancer treatments, including cell therapies and bispecific drugs, for patients with advanced cancers. It last closed at $6.29 on Nov 17, up 1.94% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From IMTX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 5). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on IMTX in the past 90 days. The average target is $15.00, with a high of $15.00 and a low of $15.00, compared with the last close of $6.29.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 14 | Stifel | Initiated | Buy | $15 |
| May 19 | Chardan Capital | Maintained | Buy | $25 |
Technical Analysis
The stock is 9% below its 20 day and 20% below its 50 day average. It is 49% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot at $6.22, and the nearest resistance the Pivot R1 at $6.37.
| RSI (14) | 36.16 | Weak, oversold below 30 | Neutral |
| MACD | -0.37 | Below its signal line | Bearish |
| Stochastic | 14.4 | Near the bottom of its range | Oversold |
| ADX (14) | 30.5 | Trending down | |
| Williams %R | -84.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -102.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −11.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.43 | Typical daily range, 6.9% of price |
| RSI (14) | 31.38 | Weak, oversold below 30 | Neutral |
| MACD | -0.87 | Below its signal line | Bearish |
| Stochastic | 6.8 | Near the bottom of its range | Oversold |
| ADX (14) | 34.7 | Trending down | |
| Williams %R | -94.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -130.7 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −28.4% | Change over 10 sessions | Bearish |
| ATR (14) | $1.01 | Typical daily range, 16.1% of price |
What happened before
See how IMTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IMTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in IMTX in the last 90 days.
IMTX Institutional Ownership
Full report →- ▲61 buying vs 35 selling
- ▲Shares held by funds +11.3%
- ▲Funds holding +7
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 91 | 84 | +8.3% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 22 / 39 | 12 / 25 | +64.9% |
| Reduced / sold out | 21 / 14 | 34 / 13 | −25.5% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMTX is in one of them and how their past IMTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IMTX in an article yet. Here's the latest on the wider market.
About Immatics N.V.
Immatics is a biopharmaceutical company based in Tubingen, Germany, that develops cancer treatments aimed at PRAME, a protein found on the surface of many tumor cells. Its main products are T cell receptor therapies in two forms. Its cell therapies are made individually for each patient, while its bispecific drugs are made in advance and distributed through standard pharmaceutical supply channels. The treatments are intended for patients with advanced cancers, such as melanoma, and are given through specialized hospitals and medical centers.
- Headquarters
- Tubingen, Germany


